Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: Concurrent expression in cancer cells from primary tumour and metastatic lymph node

被引：61
作者：
Saintigny, Pierre
Kambouchner, Marianne
Ly, Madani
Gomes, Noelia
Sainte-Catherine, Odile
Vassy, Roger
Czernichow, Sebastien
Letoumelin, Philippe
Breau, Jean-Luc
Bernaudin, Jean-Francois
Kraemer, Michel
机构：
[1] Hop Avicenne, Med Oncol Serv, AP HP, F-93009 Bobigny, France
[2] Univ Paris 13, Lab Oncol Cellulaire & Mol, EA 3410, Bobigny, France
[3] Hop Avicenne, Serv Anat & Cytol Pathol, AP HP, F-93009 Bobigny, France
[4] Univ Paris 06, Hop Tenon, Serv Histol Biol Tumorale, EA 3499, Paris, France
[5] Hop Avicenne, AP HP, Bobigny, France
[6] Hop Avicenne, Dept Interhosp Sante Publ, AP HP, Bobigny, France
来源：
LUNG CANCER | 2007年 / 58卷 / 02期
关键词：
vascular endothelial growth factor-C;
D O I：
10.1016/j.lungcan.2007.06.021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Introduction: Investigation of the role of vascular endothelial growth factor-C (VEGF-C) and VEGF receptor-3 (VEGFR-3) in non-small-cell lung cancer (NSCLC) has mainly focused on lymph node (LN) metastasis related to lymphangiogenesis. However, the coexpression of VEGF-C/VEGFR-3 by tumour cells can independently play an important role.
引用
收藏
页码：205 / 213
页数：9
相关论文
共 36 条
[1]   Tumor lymphangiogenesis and metastatic spread - New players begin to emerge [J].
Achen, Marc G. ;
Stacker, Steven A. .
INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (08) :1755-1760
[2]   The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer [J].
Achen, MG ;
Williams, RA ;
Baldwin, ME ;
Lai, P ;
Roufail, S ;
Alitalo, K ;
Stacker, SA .
GROWTH FACTORS, 2002, 20 (02) :99-107
[3]   Clinical significance of vascular, endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma [J].
Arinaga, M ;
Noguchi, T ;
Takeno, S ;
Chujo, M ;
Miura, T ;
Uchida, Y .
CANCER, 2003, 97 (02) :457-464
[4]   Prognostic factors in non-small cell lung cancer - A decade of progress [J].
Brundage, MD ;
Davies, D ;
Mackillop, WJ .
CHEST, 2002, 122 (03) :1037-1057
[5]  
CAO Y, 2005, NAT REV CANCER, V5, P1
[6]   Flt-4-positive endothelial cell density and its clinical significance in non-small cell lung cancer [J].
Chen, FS ;
Takenaka, K ;
Ogawa, E ;
Yanagihara, K ;
Otake, Y ;
Wada, H ;
Tanaka, F .
CLINICAL CANCER RESEARCH, 2004, 10 (24) :8548-8553
[7]   Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy [J].
Dias, S ;
Choy, M ;
Alitalo, K ;
Rafii, S .
BLOOD, 2002, 99 (06) :2179-2184
[8]  
Ginsberg Robert J., 1997, P858
[9]   Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels [J].
He, YL ;
Rajantie, I ;
Pajusola, K ;
Jeltsch, M ;
Holopainen, T ;
Yla-Herttuala, S ;
Harding, T ;
Jooss, K ;
Takahashi, T ;
Alitalo, K .
CANCER RESEARCH, 2005, 65 (11) :4739-4746
[10]   Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling [J].
He, YL ;
Kozaki, KI ;
Karpanen, T ;
Koshikawa, K ;
Yla-Herttuala, S ;
Takahashi, T ;
Alitalo, K .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (11) :819-825
1234